Skip to content
Investment Visual
/
Backtest
Tools
Browse
Stocks
ILMN
Financials
Revenue by segment
ILMN
Illumina, Inc.
Backtest
ILMN
Overview
Returns
Financials
Holders
Insiders
Summary
Statements
Income
Revenue
Revenue by segment
Revenue by region
Gross profit
Operating income
Net income
EPS
EBITDA
Cash flow
Balance sheet
Valuation
Shares and dividends
Costs
Revenue by segment
Segments
Products
Annual
Quarterly
Revenue by segment
Segments
Products
Annual
Quarterly
FY2025, ended Dec 28, 2025
Sequencing
$4.0B
92%
Microarray
$358M
8%
Earlier:
Core Illumina
to FY2018
Helix
to FY2019
Eliminations
to FY2019
Segments by fiscal year
CSV
Segments by fiscal year
USD
Line, in USD
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
FY2017
FY2016
Core Illumina
—
—
—
—
—
—
3.54B
3.33B
2.75B
2.43B
Sequencing
3.99B
3.99B
4.11B
4.17B
4.11B
2.88B
3.07B
—
—
—
Microarray
358M
379M
392M
413M
417M
360M
475M
—
—
—
Eliminations
—
—
—
—
—
—
−1.0M
−11M
−8.0M
−30M
Helix
—
—
—
—
—
—
1.0M
10M
6.0M
—
Total
4.34B
4.37B
4.50B
4.58B
4.53B
3.24B
3.54B
3.33B
2.75B
2.40B
More Illumina financials
Revenue
Revenue by region
Gross profit
Operating income
Net income
EPS
Revenue at other companies
MCK
McKesson Corporation
BSX
Boston Scientific Corporation
VRTX
Vertex Pharmaceuticals Incorporated
NTRA
Natera, Inc.
ELV
Elevance Health, Inc.
HUM
Humana Inc.
Tools
Return calculator